Skip to main content

Advertisement

Log in

Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Behcet’s disease is an inflammatory disorder of unknown cause, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. All these common manifestations are self-limiting except for the ocular attacks. The objective of the present study is to report the efficacy of pentoxifylline for ocular involvement in Behcet’s disease. We report a patient with ocular involvement secondary to Behcet’s disease which was corticosteroid dependent and refractory to azathioprine treatment. Pentoxifylline was added with amelioration of inflammation. Pentoxifylline may be a useful treatment option in patients with Behcet’s disease, where other immunosuppressives have failed or are contra-indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kaklamani VG, Vaiopoulos G, Kaklamanis PH (1998) Behçet’s disease. Semin Arthritis Rheum 27:197–217

    Article  PubMed  CAS  Google Scholar 

  2. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341(17):1284–1291

    Article  PubMed  CAS  Google Scholar 

  3. Nussenblatt RB (1997) Uveitis in Behçet’s disease. Int Rev Immunol 14:67–79

    Article  PubMed  CAS  Google Scholar 

  4. Kaklamani VG, Kaklamanis PG (2001) Treatment of Behçet’s disease—an update. Semin Arthritis Rheum 30:299–312

    Article  PubMed  CAS  Google Scholar 

  5. Yazici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 42:796–804

    Article  PubMed  CAS  Google Scholar 

  6. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2009) Management of Behçet disease: a systematic literature review for the European League against rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 68:1528–1534

    Article  PubMed  CAS  Google Scholar 

  7. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  8. Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136

    Article  PubMed  CAS  Google Scholar 

  9. BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 70:589–592

    Article  PubMed  CAS  Google Scholar 

  10. Kural-Seyahi E, Fresko I, Seyahi N (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76

    Article  Google Scholar 

  11. Ehrlich GE (1997) Vasculitis in Behçet’s disease. Int Rev Immunol 14:81–88

    Article  PubMed  CAS  Google Scholar 

  12. Matsumura N, Mizushima Y (1975) Leucocyte movement and colchicine treatment in Behcet’s disease. Lancet 2:813

    Article  PubMed  CAS  Google Scholar 

  13. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402

    PubMed  CAS  Google Scholar 

  14. Thornhill MH, Baccaglini L, Theaker E, Pemberton MN (2007) A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 143:463–470

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simone Appenzeller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Appenzeller, S., Hazel, E. Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers. Rheumatol Int 31, 1511–1513 (2011). https://doi.org/10.1007/s00296-009-1305-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1305-9

Keywords

Navigation